Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hopital Universitaire Robert-Debre | OTHER |
| University of Cambridge | OTHER |
| Mario Negri Institute for Pharmacological Research | OTHER |
Not provided
Not provided
Not provided
Not provided
Tertiary lesions responsible of the neurological decline after severe traumatic brain injury (TBI) are partially due to a persistent neuro-inflammation directly modulated by inflammatory mediators during the acute phase and detectable by using both multimodal MRI imaging and biological biomarkers during the acute phase after traumatic brain injury.
The main objective is to identify if the level of IL-1beta in cerebrospinal fluid predict in a reliable and reproducible way, the neuro-radiological evolution evaluated by the comparison of a quantitative MRI performed in post-resuscitation and at one year (quantitative ΔIRM) in traumatic brain injuried patients.
The secondary objectives are:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Biological Collection | Experimental | Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biological Collection | Biological | Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year |
| Measure | Description | Time Frame |
|---|---|---|
| Interleukin-1 level in blood predict changes in brain volume assessed by quantitative MRI. | Brain volume evolution assessed by quantitative MRI between Day 42 and Day 365 | Day 42 and 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Concentrations of biomarkers such as Tau protein and beta-amyloid plaques in serum and cerebrospinal fluid (Aβ1-42, T-tau, and P-tau181P and Interleukin 1) | Plasma and Serum biological collection, multimodal MRI database, clinical database | Blood and CSF samples collected at Day1, Day2, Day3, Day5 and Day7 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Vincent Degos, PU-PH | Contact | 01 42 16 37 61 | vincent.degos@aphp.fr | |
| Gregory Torkomian, Master | Contact | 01 42 16 37 01 | gregory.torkomian@aphp.fr |
| Name | Affiliation | Role |
|---|---|---|
| Vincent Degos, PU-PH | Assistance Publique - Hôpitaux de Paris | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Anesthesy department - Hôpital Pitié Salpêtrière | Recruiting | Paris | 75013 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000070642 | Brain Injuries, Traumatic |
| ID | Term |
|---|---|
| D001930 | Brain Injuries |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D006259 |
| Craniocerebral Trauma |
| D020196 | Trauma, Nervous System |
| D014947 | Wounds and Injuries |